Feasibility of Lophius Kits T-Track® CMV and T-Track® EBV to assess the functionality of cell-mediated immunity (CMI) in hemodialysis patients

P80

  • Banas, B.
  • Böger, C.
  • Lückhoff, G.
  • Krüger, B.
  • Batzilla, J.
  • Schemmerer, M.
  • Starke, A.
  • Köstler, J.
  • Deml, L.
  • Leicht, J.
  • Krämer, B.

  • 1University Medical Center Regensburg, Internal Medicine II, Regensburg, Deutschland;

    2Dialysis Center Landshut, Landshut, Deutschland;

    3University Medical Center Mannheim, 5th Department of Medicine, Mannheim, Deutschland;

    4Lophius Biosciences GmbH, Regensburg, Deutschland;

    5University Medical Center Regensburg, Institute of Medical Microbiology and Hygiene, Regensburg, Deutschland;

    6Dialysis Center Schwandorf, Schwandorf (Bayern), Deutschland

Clinical Chemistry and Laboratory Medicine 50(9):p A250, September 2012.
Copyright © 2012 Walter de Gruyter